Relapse in cancer patients undergoing CAR therapy can occur due to cancer cells downregulating surface antigens. With CARs utilizing CD19 as a target to locate and eliminate cancers, downregulation of CD19 poses a challenge to CAR-mediated therapy.
We are investigating the potential of CAR NK cells to target cancer cells with low amounts of surface CD19 antigen as a method to overcome relapse in patient cases with downregulated surface CD19 antigen.
We are investigating the potential of CAR NK cells to target cancer cells with low amounts of surface CD19 antigen as a method to overcome relapse in patient cases with downregulated surface CD19 antigen.